FPR2 and diabetic kidney disease: Studies performed in diabetic nephropathy model induced by streptozotocin in SD rats, showed that MSCs treatment significantly increased LXA4 and ALX/FPR2, the receptor of LXA4, expression in renal tissue of these animals.